|
| Author, year (country) | Trials (subjects) | Intervention group | Control group | Mode of administration | Quality assessment | Main results |
|
| Saurabh Chandan, 2020 (USA) [20] | 7 (380) | Curcumin+mesalamine | Placebo+mesalamine | Oral administration, enema administration | Jadad | According to our research, compared with placebo, the clinical remission rate of mesalazine and curcumin combined treatment is about 3 times higher, and the side effects are minimal. This response is statistically significant, although there is heterogeneity, it may be due to the severity score index, the dose of curcumin, and the route of administration used. |
| Armin Ebrahimzadeh, 2021 (Iran) [21] | 2 (104) | Curcumin+CT | Placebo+CT | Oral administration | Cochrane | Curcumin supplementation is associated with a significant decrease in CRP and ESR levels in patients with ulcerative colitis. |
| Ricardo de Alvares Goulart, 2020 (Brazil) [22] | 4 (238) | Curcumin+CT | Placebo+CT | Oral administration | GRADE | Based on our results, we can say that the use of curcumin has a beneficial effect on the clinical remission of UC patients. However, when treating UC, we need to consider curcumin carefully, because more robust and well-designed studies are needed. |
| Umair Iqbal, 2018 (USA) [23] | 3 (142) | Curcumin+mesalamine | Placebo+mesalamine | Oral administration, enema administration | Jadad | This study shows that when curcumin is used in combination with mesalazine to achieve remission in UC patients, the clinical remission rate is higher. Because of its cost-effectiveness and safer side effects, curcumin can reduce the medical burden and morbidity associated with this recurrent and recurrent disease.. |
| Maria G. Grammatikopoulou, 2018 (Greece) [24] | 3 (194) | Curcumin+mesalamine | Placebo+mesalamine | Oral administration | Cochrane | Based on the currently available evidence, oral curcumin does not appear to be superior to placebo in alleviating the condition of UC patients. |
| Ting Zheng, 2020 (China) [25] | 6 (349) | Curcumin+CT | Placebo+CT | Oral administration, enema administration | Cochrane | In short, curcumin is an effective and safe drug that can be used in the treatment of UC together with standard treatments. |
| Liwei Zhu, 2019 (China) [26] | 5 (261) | Curcumin+CT | Placebo+CT | Oral administration, enema administration | Cochrane | Our systematic review and meta-analysis showed that curcumin combined with mesalazine as an adjuvant drug can significantly increase the clinical remission rate, DAI improvement rate, and mucosal healing rate of mesalamine. |
|
